[摘要] 目的 探讨重组人生长激素（rhGH）联合VD3滴剂辅助成长体操对矮小症患儿生长发育及25-（OH）D水平的干预作用。方法 选取2018年1月～2020年7月我院矮小症患儿66例，依据随机数字表法分为研究组与对照组，各33例。常规干预及成长体操基础上对照组采取VD3滴剂，研究组在对照组基础上采取rhGH。统计两组治疗前后生长情况、胰岛素样生长因子-1（IGF-1）、血糖指标、甲状腺功能指标（FT3、FT4、TSH）水平、不良反应。结果 治疗6个月、12个月后研究组生长速率、骨龄、身高高于对照组（P＜0.05）；治疗6个月、12个月后研究组血清IGF-1水平高于对照组（P＜0.05）；治疗6个月、12个月后两组FGIR、GLU水平与治疗前无显著差异（P＞0.05），且治疗后组间比较无显著差异（P＞0.05）；治疗6个月、12个月后两组FT3、FT4、TSH水平与治疗前无显著差异（P＞0.05），且治疗后组间比较无显著差异（P＞0.05）；研究组不良反应发生率（15.15%）与对照组（9.09%）间无显著差异（P＞0.05）；治疗后研究组25-（OH）D水平高于对照组。结论 联合采取VD3滴剂、成长体操及rhGH对矮小症患儿实施干预，可有效促进其生长发育，增加25-（OH）D含量，调节IGF-1水平，且对血糖及甲状腺功能影响小，不会增加不良反应发生风险，具有安全性。

[Abstract] Objective To explore the effect of recombinant human growth hormone (rhGH) combined with VD3 drops on growth and development gymnastics on growth and development and 25-(OH)D level in children with dwarfism. Methods From January 2018 to March 2020, 66 children with dwarfism in our hospital were selected and divided into a study group and a control group according to the random number table method, 33 cases each. The control group took VD3 drops on the basis of routine intervention and growth gymnastics, and the study group took rhGH on the basis of the control group. The growth, insulin-like growth factor-1 (IGF-1), blood glucose indexes, thyroid function indexes (FT3, FT4, TSH) levels and adverse reactions were counted before and after treatment in both groups. Results After 6 months and 12 months of treatment, the growth rate, bone age and height of the study group were higher than those of the control group (P<0.05); after 6 months and 12 months of treatment, the serum IGF-1 level in the study group was higher than that in the control group, and the Ghrelin level was lower than that in the control group (P<0.05); after 6 months and 12 months of treatment, the levels of FGIR and GLU of the two groups were not significantly different from those before treatment (P>0.05), and there was no significant difference between the groups after treatment (P>0.05); the levels of FT3, FT4 and TSH in the two groups after 6 months and 12 months of treatment were not significantly different from those before treatment (P>0.05), and there was no significant difference between the groups after treatment (P>0.05); there was no significant difference between the incidence of adverse reactions in the study group (15.15%) and the control group (9.09%) (P>0.05); after treatment, the 25-(OH)D level in the study group was higher than that in the control group. Conclusion The combined use of VD3 drops, growth gymnastics and rhGH to intervene in children with dwarfism can effectively promote their growth and development, increase the content of 25-(OH)D, and regulate IGF-1 levels, and has little effect on blood glucose and thyroid function, does not increase the risk of adverse reactions, and is safe.